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Patients are receiving treatment that may be unsound as 
investigations by Ian Roberts, Richard Smith, and  
Stephen Evans raise questions about whether influential 
trials of high dose mannitol ever took place
E
ach year, worldwide, many thou-
sands of people are treated in 
emergency departments for head 
injuries. Mannitol is an osmotic 
diuretic that is believed to reduce 
intracranial pressure after head injury and 
may improve patient outcome. Between 
2001 and 2004, a Brazilian neurosurgeon 
Julio Cruz and colleagues published three 
clinical trials comparing high dose and con-
ventional dose mannitol in the treatment 
of head injury (table).1-3 No other trials had 
examined this question. 
The results showed that high dose manni-
tol greatly reduced death and disability six 
months after the head injury. A Cochrane 
systematic review that included these trials 
concluded: “high dose mannitol seems to 
be preferable to conventional dose man-
nitol in the acute management of comatose 
patients with severe head injury.”4 How-
ever, one of the trials was accompanied 
by an editorial that questioned the reliabil-
ity and validity of the results, calling for 
further multicentre studies.5 A subsequent 
investigation by the Cochrane Collabora-
tion was unable to confirm that the studies 
took place.
Doubts over the data
In May 2006, Dr Jorge Mejia, the Colom-
bian national coordinator of the CRASH-2 
(clinical randomisation of an antifibrino-
lytic in significant haemorrhage; www.
crash2.Lshtm.ac.uk) trial, wrote to IR (who 
is editor of the Cochrane Injuries Group) 
after attending a meeting of the Latin 
American Brain Injury Consortium in Bra-
zil. He was concerned about the inclusion 
of the Cruz trials in the Cochrane review:
“During the discussion some Brazilian 
physicians expressed some surprise with 
the inclusion of Julio Cruz’ paper in the 
meta-analysis (Cruz 2004; J Neurosurgery, 
100:376) … Cruz had no patients at his 
arrival to Brasil, back from USA where he 
had developed his research career.”
Dr Mejia was clearly shocked by this 
revelation: “I do not know what to do, 
but I feel betrayed. I guess that someone 
should contact the other authors and ask 
them. I feel that I can not stay passive, but 
I have no evidence.”
Dr Cruz, the lead author, had killed 
himself in 2005. However, the reports had 
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table 1 | Details of trials of high dose mannitol
Authors Patients Intervention Outcome Results Odds ratio (P value)
High dose Low dose
Cruz J, Minoja G, Okuchi K1 178 adults with non-missile, traumatic 
acute subdural haematomas
High dose mannitol v lower  
dose mannitol
Death at 6 months 13/91 22/87 0.49 (0.06)
Death or severe disability at 6 
months
28/91 47/87 0.38 (0.002)
Cruz J, Minoja G, Okuchi K2 141 patients with traumatic, non-missile, 
acute, intraparenchymal temporal lobe 
haemorrhages associated with early 
abnormal pupillary widening
High dose mannitol v lower  
dose mannitol
Death at 6 months 14/72 25/69 0.42 (0.03)
Death or severe disability at 6 
months
28/72 46/69 0.32 (0.001)
Cruz J, Minoja G, Okuchi K, 
Facco E3
44 adults with traumatic, non-missile, 
acute, severe, diffuse brain swelling with 
recent clinical signs of impending brain 
death
Very early and fast high dose 
mannitol v lower dose mannitol
Death at 6 months 9/23 14/21 0.32 (0.07)
Death or severe disability at 6 
months
13/23 19/21 0.14 (0.01)
crystals of mannitol—the drug believed to reduce 
intracranial pressure after head injury
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coauthors from Italy and Japan, and we 
contacted them for further information.
Dr Minoja wrote on 15 May 2006: 
 “It was a pleasure for me to be included 
along the authors of the papers written 
by Julio Cruz on the use of high doses of 
mannitol in head trauma emergencies. My 
Unit and I did not provide to Dr. Cruz a 
personal series of randomized patients, but 
my contribution was discussing with him 
and sharing his assumption, because occa-
sionally, in emergency situations, I have 
used and I still use with success aggressive 
high-dose mannitol approach.” 
In a second message, he wrote: “I think 
that patients were enrolled in USA and 
more recently in Brazil, but I honestly don’t 
know the period and in what Institution.”
Dr Okuchi responded: 
“Since I did not conduct any study related 
to the results of Dr Cruz’s high-dose manni-
tol trials in Japan, I have no data to present 
you. I did not know any part of the paper 
before he called me about the acceptance in 
the journal every time” (18 May 2006).
Dr Facco wrote:
 “The paper I am co-author, springs 
from the clinical experience I shared with 
Julio Cruz about the potential effectiveness 
of high doses of mannitol in selected very 
critical patients. I discussed with him (mainly 
by phone) about my anecdotal experience 
I never had the opportunity to check in a 
prospective study, and he also had the same 
clinical impression of its effectiveness ... 
Following our discussion, he decided to test 
high mannitol doses in the emergency set-
ting and involved me as co-author, but my 
role was ‘philosophical’ rather than clinical: 
to my knowledge, the study was conducted 
personally by Julio, probably in Brazil, and 
I only helped him with discussion and text 
revision” (22 May 2006).
Since none of the authors could pro-
vide any reassurance about the integrity 
of data, the Cochrane systematic review 
was withdrawn in 2006 while an investiga-
tion was made.
The Cruz papers were published in 
Neurosurgery and the Journal of Neurosurgery 
and we wrote to the editors about the 
concerns. In July 2006, John Jane, the editor 
of the Journal of Neurosurgery wrote:
“I have tried unsuccessfully to contact 
you by phone with regard to the Cruz 
papers. As you can tell by Dr. Marshall’s 
editorial, we all doubted the data. But to 
doubt is different from concluding that Dr. 
Cruz fabricated the data. I thought he did, 
but hoped as stated in the editorial that 
publication would encourage repetition of 
the studies. My Editorial Board thought Dr. 
Cruz’ work should be published. I wouldn’t 
trust the data.”
The editorial by Dr Marshall which 
accompanied the Journal of Neurosurgery 
report stated: 
“These results are clearly of substantial 
interest, but also raise questions about 
how reliable and valid are clinical studies 
that show very dramatic improvements 
in outcome when they are performed 
at only one institution. This does not 
demean the work of Dr Cruz and his 
colleagues; rather it indicates that multi- 
centre studies, such as those being con-
ducted at present for novel pharmaco-
logical therapies, need to be applied to 
alternative dosing regimens for more 
traditional methodologies.”5 
We asked Dr Marshall if he had any 
concerns about the integrity of the data. 
He would not respond in writing but 
he left a phone message saying that he 
had “serious concerns” about the paper 
(8 August 2006).
The editorial office of Neurosurgery wrote:
“With a serious charge, the possible fabri-
cation of trials, a case must formally be pre-
sented with any and all possible evidence 
that would indicate the cause for concern 
and the reviewers must then address the 
issue. It is not possible or responsible for 
the Editor of a peer-reviewed journal to act 
hastily in such a matter without the input of 
the reviewers who originally accepted the 
paper, nor would it be responsible to simply 
pull the papers without presentation of the 
results of an investigation into the matter. 
An unsubstantiated claim and verbal reci-
tation of the inquiries made cannot suffice” 
(8 December 2006). 
We have had no further correspondence.
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Where did the patients come from?
None of the reports indicated where the 
patients came from. All of them stated that 
“institutional review board approval was 
obtained” but gave no further details. On 
each report, the Dr Cruz’s affiliation was 
the “Comprehensive International Centre 
for Neuroemergencies and Federal Univer-
sity of São Paulo.” Reprint requests were 
to the centre at a postal box address in São 
Paulo. We were unable to find any further 
information about the centre. In October 
2006, the Federal University of São Paulo 
stated in response to our inquiry that it had 
never employed Dr Cruz.
We also wrote to the Brazilian national 
committee on ethics in research, which 
began an investigation. The investigation 
found that Dr Cruz had given an interview 
in which he said that the patients in one of 
the trials were from eight hospitals in Bra-
zil, Italy, and Japan. However, the authors 
from Italy and Japan had told us that they 
did not enrol any patients at their hospitals. 
Dr Minoja had said that he thought that 
the patients might have been recruited in 
the US (15 May 2006). We contacted the 
University of Pennsylvania, where Dr 
Cruz had worked until March 1995. They 
searched their records but found no indica-
tion that the research was conducted there 
(Steven Fluharty, personal communication, 
8 December 2006).
In September the Committee on Publi-
cation Ethics recommended that the living 
authors seek retraction of the reports on the 
basis that they were gift authors and could not 
take responsibility for the results. We wrote to 
all three coauthors on 21 September asking if 
they would be willing to seek retraction.
Dr Okuchi replied the next day: “I 
would like to retract these papers from 
the journals because I am not able to take 
responsibility for the content. Could you 
let me know how to act formally for the 
purpose.” A few days later (25 Septem-
ber) he wrote again, “On my last e-mail 
letter, I had mentioned withdrawal of the 
papers, however I found that I had no 
right to retract the papers from the jour-
nals. I think it depends on whether Dr 
Cruz will decide or not ... I will contact 
him in a few days.”
IR wrote again to the coauthors on 10 
October explaining that Dr Cruz was dead, 
stating that “it would be wrong of me not to 
follow up this matter and so unless you con-
tact the journals in question to seek retrac-
tion I will have to write to your institutions 
to ask for their help. It is an unfortunate 
business but it will be better for everyone 
concerned that you take the appropriate 
steps to resolve this matter.”
Later that month (27 October), Dr Facco 
wrote on behalf of Dr Minoja and Dr 
Okuchi. He said that they did not believe 
that they were gift authors and declined to 
seek retraction. He argued that the papers 
were published in an international peer 
reviewed journal, that the first author had 
taken responsibility for their content, and that 
they knew the first author well and believed 
that “he would never have been able to do 
something false.”
Wider implications
We are left with serious doubt about impor-
tant studies but with no way of determin-
ing with confidence whether the results are 
fabricated or real. The main author is dead. 
There is no institution to investigate. The 
implications for patients are serious. They 
are being treated on the basis of potentially 
unreliable evidence. It is plausible that man-
nitol in high doses may increase rather than 
decrease brain swelling.6 Shortly after the 
withdrawal of the Cochrane review, the 
Cochrane Injuries Group was contacted 
by US researchers preparing guidelines for 
the management of severe traumatic brain 
injury and by BMJ Clinical Evidence asking 
about the outcome of our investigation 
because the Cruz results were about to be 
incorporated into guidelines.
There are also implications for the 
broader scientific community. Earlier this 
year an investigation by Science of more 
than a dozen fraud or suspected fraud 
cases showed “uneven and often chaotic 
efforts to correct the scientific literature.”7 
If it wants to retain the confidence of the 
public and politicians, the scientific com-
munity needs to do better. Only a minor-
ity of countries have an effective national 
system for responding to scientific mis-
conduct. However, research is a global 
enterprise and a strong case exists for an 
international body to respond to the prob-
lem of research misconduct.
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Should high dose mannitol be used to treat head 
injury? 
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